Arcus Biosciences (RCUS) EBITDA Margin Growth (1y) (2018 - 2026)

Arcus Biosciences (RCUS) EBITDA Margin Growth (1y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -143.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 78.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 1,049.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1,238.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -7.76 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn - -1,651.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 2,002.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 29,091.00
10 Arcus Biosciences 3.74 Bn 3.04 Bn - -22,915.00

Historic Data

Download Data
DateValue
Jun 30, 2026 -22,915.00
Mar 31, 2026 -35,252.00
Dec 31, 2025 5,070.00
Sep 30, 2025 -32,740.00
Jun 30, 2025 26,679.00
Mar 31, 2025 -42,468.00
Dec 31, 2024 25,385.00
Sep 30, 2024 3,125.00
Jun 30, 2024 1,441.00
Mar 31, 2024 33,297.00
Dec 31, 2023 -43,235.00
Sep 30, 2023 -3,788.00
Jun 30, 2023 -3,065.00
Mar 31, 2023 2,822.00
Dec 31, 2022 -29,689.00
Sep 30, 2022 61,375.00
Jun 30, 2022 54,918.00
Mar 31, 2022 39,669.00
Dec 31, 2021 62,501.00
Sep 30, 2021 -82,828.00